ABSSSI market to hit $20.79 billion by 2030

The acute bacterial skin and skin structure infections market is projected to grow from $12.9 billion in 2025 to $20.79 billion by 2030, driven by rising infection rates, broader antibiotic use and faster diagnostics. Asia-Pacific led the market in 2025, while North America is expected to be the fastest-growing region.

Why it matters: - The acute bacterial skin and skin structure infections market is expanding as more patients need treatment for common but potentially serious skin infections. - Growth in effective antibiotics, combination therapies and rapid diagnostics could improve outcomes and widen treatment access. - The market forecast signals rising demand across hospitals, community care and pharmacy channels.

What happened: - The Business Research Company said the global acute bacterial skin and skin structure infections market was valued at $12.9 billion in 2025. - The market is projected to reach $14.09 billion in 2026, based on a 9.2% compound annual growth rate. - The market is forecast to reach $20.79 billion by 2030, with a 10.2% compound annual growth rate. - The company released a new report on the market on Oct. 28, 2026, from London. - A free sample of the report is available here. - The full report is available here.

The details: - Acute bacterial skin and skin structure infections affect the skin and underlying tissues. - These infections typically cause redness, swelling, pain and warmth. - Antibiotic treatment is used to prevent complications and support healing. - Market growth in the near term is linked to limited broad-spectrum antibiotic availability, more hospital-acquired infections, greater awareness of skin infection complications, improved community healthcare access and standardized infection control protocols. - The report cites rising infection rates, growing acceptance of novel antibiotics and combination therapies, expansion of healthcare facilities and broader use of oral and parenteral antibiotics as key trends. - The report also points to next-generation antibiotics, higher antimicrobial research spending, community-based infection management programs, wider hospital pharmacy distribution and rapid diagnostic technologies as growth drivers through 2030. - The market report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics, key technologies, future trends, updated graphics and tables.

Between the lines: - The market outlook reflects a shift from basic treatment demand toward faster diagnosis, broader care delivery and more targeted antibiotic strategies. - WHO data cited in the release underscores the scale of the underlying disease burden, with about 1.8 billion people globally affected by skin conditions at any given time as of March 2023. - In that WHO breakdown, neglected tropical diseases account for about 10% of cases, fungal infections 34% and bacterial infections 23%. - Asia-Pacific was the largest regional market in 2025. - North America is expected to post the fastest growth over the forecast period.

What's next: - Market growth will likely track investment in antimicrobial research and the pace of new antibiotic development. - Broader use of rapid diagnostics and community-based infection management programs could shape how quickly patients are treated. - Regional demand may continue to diverge, with Asia-Pacific retaining scale and North America adding growth momentum. - The company invited readers to contact its experts for more information.

The bottom line: - Acute bacterial skin and skin structure infections are becoming a bigger commercial and clinical market, with the category expected to rise from $12.9 billion in 2025 to $20.79 billion by 2030.